Creso Pharma : Initial Director's Interest Notice x3

For personal use only

Appendix 3X

Initial Director's Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity Creso Pharma Limited
ABN	609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Bruce Linton
Date of appointment	17 January 2022

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities

Nil

Part 2 - Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of	Number & class of Securities
interest
Bruce Linton	30,000,000 CPHOPT33 Unlisted Options ($0.039,
2040 A/C>	23/12/2025)

• See chapter 19 for defined terms. 11/3/2002

Appendix 3X Page 1

Appendix 3X

Initial Director's Interest Notice

Part 3 - Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

only
Detail of contract	Subject to the continued service of Mr Bruce
		Linton, the Board will also seek approval of
		shareholders at its general shareholder
		meeting for a grant of Options to Mr Bruce
		Linton (or his nominees). The grant for which
		approval will be sought will be for 10,000,000
		options with an exercise price of 9c and an
use		expiry date that is two years following the
	Director's commencement date.
Nature of interest	N/A
	Name of registered holder	N/A
	(if issued securities)
For personal	No. and class of securities to which	10,000,000 Unlisted Options ($0.09, 17 Jan
interest relates	2024)

+ See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002

For personal use only

Appendix 3X

Initial Director's Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity Creso Pharma Limited
ABN	609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Micheline MacKay
Date of appointment	17 January 2022

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities

Nil

Part 2 - Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of	Number & class of Securities
interest
Nil	Nil

Part 3 - Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A

• See chapter 19 for defined terms. 11/3/2002

Appendix 3X Page 1

For personal use only

Appendix 3X

Initial Director's Interest Notice

Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
No. and class of securities to which	N/A
interest relates

+ See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002

For personal use only

Appendix 3X

Initial Director's Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity Creso Pharma Limited
ABN	609 406 911

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	William Lay
Date of appointment	17 January 2022

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities

Nil

Part 2 - Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of	Number & class of Securities
interest
Noble House Consulting Ltd	5,000,000 Ordinary Shares
(a director related entity)	1,666,667 CPHO Listed Options
	($0.25, 2/11/2024)
	10,000,000	CPHOPT41	Unlisted	Options
	($0.18, 6/09/2024)
	10,000,000	CPHOPT42	Unlisted	Options
	($0.25, 6/09/2024)
	15,000,000	CPHPERR43	Performance Rights
	(Nil, 17/09/2023)

+ See chapter 19 for defined terms.

11/3/2002

Appendix 3X Page 1